MRCM
PMVP icon

M&R Capital Management’s PMV Pharmaceuticals PMVP Stock Holding History

M&R Capital Management’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5
Closed – – 448
2022
Q1 		$0 Hold
5
– – ﹤0.01% 444
2021
Q4 		$0 Hold
5
– – ﹤0.01% 425
2021
Q3 		$0 Hold
5
– – ﹤0.01% 427
2021
Q2 		$0 Buy
+5
New +$167 ﹤0.01% 430

Other funds holding PMVP

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

M&R Capital Management's PMVP Position: Q2 2022 in Review

M&R Capital Management sold out of PMV Pharmaceuticals (PMVP) in Q2 2022, closing a stake of 5 shares.

M&R Capital Management first reported a position in PMVP in Q2 2021 and held it in 4 quarters. The position peaked at $0 in Q1 2022. 105 funds tracked by Wall St. Rank hold PMVP as of Q2 2022.

  • M&R Capital Management reported no remaining PMV Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • M&R Capital Management sold 5 PMV Pharmaceuticals shares in Q2 2022.
  • M&R Capital Management first reported a position in PMV Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • M&R Capital Management's PMV Pharmaceuticals position peaked at $0 in Q1 2022.
  • 105 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2022.

Based on M&R Capital Management's 13F filing for Q2 2022, filed 5 Jul 2022.